HEALTH● LOWAug 12 · Aug 12, 2026, 2:58 PM
Acumen anticipates mid-2027 IND filing for lead EBD candidate while keeping Phase II ALTITUDE-AD topline results on track for late 2026
Seeking Alpha Tech
Acumen anticipates filing an Investigational New Drug (IND) application for its lead EBD candidate by mid-2027, with Phase II ALTITUDE-AD trial results expected in late 2026. This announcement details key milestones in the development of a potential new medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH51m agoThe lesson of La Guajira for measuring health in ColombiaLa Silla VacíaHEALTH1h agoBayern coach Kompany taken to hospital after collapsing during trainingAl Jazeera [en]HEALTH1h agoBayern Munich manager Vincent Kompany hospitalised after collapse during trainingEuroNews [en]HEALTH1h agoKeralam to conduct Statewide child vulnerability mappingThe Hindu